Month: January 2023

Harvest volumes Q4 2022 (1)Farming Norway 87.0 thousand tonnesFarming Scotland 10.5 thousand tonnesFarming Chile 18.5 thousand tonnesFarming Canada 11.0 thousand tonnesFarming Ireland 0.5 thousand tonnesFarming Faroes 3.0 thousand tonnesTotal 130.5 thousand tonnes   In connection with the presentation of the Q3 2022 results, Mowi ASA guided a total harvest volume of 127 thousand tonnes (GWE) for Q4 2022. Full year harvest volumes were 464 thousand tonnes. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWE). Additional information Operational EBIT for the Group was approximately EUR 239 million in Q4 2022 (EUR 146 million in Q4 2021). Full year Operational EBIT was approximately EUR 1 005 million in 2022. Total Operational EBIT per kg through the value chain was approximately as follows:Norway EUR  ...

TAIPEI, Taiwan, Jan. 16, 2023 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today announced the appointment of Tony Yen as Head of Taiwan, effective 1 January 2023. Tony succeeds Charles Wang who retired in December 2022. Tony brings with him over 20 years of risk engineering, risk management and insurance broking experience, and joined WTW in 2015. He also heads WTW’s Corporate Risk & Broking (CRB) business in Taiwan and has helped many Taiwanese companies in developing their business continuity and enterprise risk management programmes. In his new role, Tony will work closely with business leaders across WTW to facilitate service delivery and drive growth in Taiwan. Commenting on the appointment, Simon Weaver, Head of Asia Pacific and Head of Corporate Risk & Broking,...

— China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China — — SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements expected beginning in 2023 — — Expansion of Clover’s mid- to late-stage pipeline expected starting in H1 2023, with a focus on (1) building a leading respiratory vaccine franchise and (2) establishing a presence in the pediatric vaccine market in China and the Asia Pacific — SHANGHAI, China, Jan. 15, 2023 (GLOBE...

Results in “children of the moon” disorder have implications for populations at highest risk of skin cancer MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) — Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide, a melanocortin drug under development by CLINUVEL, to protect and treat patients with xeroderma pigmentosum (XP), a rare disorder which causes extreme rates of skin cancers and forces patients to live in the dark. “XP patients are known as ‘children of the moon’ due to their need to avoid any light and sun exposure or risk severe, aggressive skin cancers from an early age,” CLINUVEL’s expert genomic scientist, Dr Jessica Nucci said. “Our first...

Expanded RFID capabilities in its store solution improves inventory accuracy, automates store processes and reduces labor costs NEW YORK, Jan. 15, 2023 (GLOBE NEWSWIRE) — Today at the NRF Big Show, Manhattan Associates Inc. (NASDAQ: MANH) unveiled its vision for an RFID-powered store. Manhattan Active® Omni suite has expanded its support of RFID tags for automating and streamlining the inventory counting, receiving, picking, checkout, return and exchange processes. With this new solution, retailers can make more accurate promises, increase conversion rates and maximize inventory exposure for selling. Retailers are increasingly depending on their stores to fulfill both in-store and online orders. However, their ability to do so is often hindered by poor store inventory accuracy, which often falls below 70%. In fact, a recent Manhattan...

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks) Efficacy was consistent over time across all endpoints, and no lessening of response (no tachyphylaxis) from roflumilast cream was observed Long-term IGA success and Intertriginous-Investigator Global Assessment (I-IGA) success results are consistent with results from the DERMIS-1 and DERMIS-2 Phase 3 clinical trials Roflumilast cream was very well-tolerated, with low rates of discontinuations due to either adverse events or lack of efficacyWESTLAKE VILLAGE, Calif., Jan. 14, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing...

DISRUPTIVE CAPITAL ACQUISITION COMPANY LIMITED(“DCAC” or the “Company”)Repurchase Offer and Stub Repurchase OfferIN RESPECT OF DCAC Shareholders (ISIN Code GG00BMB5XZ39) andDCAC Public Warrant Holders (ISIN Code GG00BMB5XY22)13 January 2023 THIS PRESS RELEASE CONTAINS INFORMATION THAT QUALIFIES OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EU MARKET ABUSE REGULATION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS Background Following release of a circular and notice of meetings to...